Detailed information for compound 1762890

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 438.328 | Formula: C19H17Cl2N3O3S
  • H donors: 1 H acceptors: 3 LogP: 3.56 Rotable bonds: 5
    Rule of 5 violations (Lipinski): 1
  • SMILES: CCS(=O)(=O)Nc1cccc(c1)c1cc(=O)n(nc1C)c1cc(Cl)cc(c1)Cl
  • InChi: 1S/C19H17Cl2N3O3S/c1-3-28(26,27)23-16-6-4-5-13(7-16)18-11-19(25)24(22-12(18)2)17-9-14(20)8-15(21)10-17/h4-11,23H,3H2,1-2H3
  • InChiKey: RVAJMPJEDUOSDF-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens androgen receptor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Loa Loa (eye worm) pyruvate kinase-PB 0.0446 0.6166 0.6166
Echinococcus granulosus pyruvate kinase 0.0639 1 1
Loa Loa (eye worm) pyruvate kinase 0.0639 1 1
Trypanosoma brucei pyruvate kinase 1 0.0639 1 0.5
Mycobacterium tuberculosis Probable pyruvate kinase PykA 0.0639 1 0.5
Echinococcus multilocularis pyruvate kinase 0.0639 1 1
Echinococcus multilocularis pyruvate kinase 0.0505 0.7331 0.5671
Onchocerca volvulus Pyruvate kinase homolog 0.0639 1 0.5
Leishmania major pyruvate kinase 0.0639 1 0.5
Brugia malayi Pyruvate kinase, M2 isozyme 0.0639 1 1
Schistosoma mansoni pyruvate kinase 0.0639 1 1
Loa Loa (eye worm) hypothetical protein 0.0639 1 1
Plasmodium falciparum pyruvate kinase 0.0639 1 1
Onchocerca volvulus Pyruvate kinase homolog 0.0639 1 0.5
Chlamydia trachomatis pyruvate kinase 0.0639 1 0.5
Loa Loa (eye worm) pyruvate kinase 0.0639 1 1
Onchocerca volvulus Pyruvate kinase homolog 0.0639 1 0.5
Entamoeba histolytica pyruvate kinase, putative 0.0446 0.6166 0.5
Trypanosoma cruzi pyruvate kinase 2, putative 0.0639 1 0.5
Trypanosoma cruzi pyruvate kinase 2, putative 0.0639 1 0.5
Plasmodium vivax pyruvate kinase, putative 0.0639 1 1
Giardia lamblia Pyruvate kinase 0.0639 1 1
Brugia malayi Pyruvate kinase, alpha/beta domain containing protein 0.0193 0.1164 0.1164
Mycobacterium ulcerans pyruvate kinase 0.0639 1 0.5
Trichomonas vaginalis pyruvate kinase, putative 0.0639 1 0.5
Loa Loa (eye worm) hypothetical protein 0.0446 0.6166 0.6166
Loa Loa (eye worm) pyruvate kinase 0.0639 1 1
Leishmania major pyruvate kinase 0.0639 1 0.5
Echinococcus multilocularis pyruvate kinase 0.0639 1 1
Trichomonas vaginalis pyruvate kinase, putative 0.0639 1 0.5
Mycobacterium leprae Probable pyruvate kinase PykA 0.0639 1 0.5
Trypanosoma brucei pyruvate kinase 1, putative 0.0639 1 0.5
Toxoplasma gondii pyruvate kinase PyK1 0.0639 1 1
Schistosoma mansoni pyruvate kinase 0.0639 1 1
Echinococcus granulosus pyruvate kinase 0.0639 1 1

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 13.19 uM Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay ChEMBL. 23727044
IC50 (functional) = 22.93 uM Cytotoxicity against human LNCAP cells assessed as cell viability after 2 days by cell counting method ChEMBL. 23727044

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.